Connecticut Advances Bill Requiring Emergency Departments to Offer Buprenorphine for Opioid Use Disorder

Dr. Cara Borelli watches patients arrive at the emergency department in withdrawal, desperate for help, only to be discharged hours later with nothing more than a referral card and vague instructions to "call on Monday." As an addiction medicine physician and emergency medicine doctor in New Haven, she knows what happens next. Many of those patients never make the Monday appointment. Some overdose within days. A few die before the week ends.

Connecticut Senate Bill 365, which received a public hearing in March and is currently under review by the Office of Legislative Research and Office of Fiscal Analysis, would change that pattern. The legislation would require every emergency department in the state to offer buprenorphine — a proven, FDA-approved medication for opioid use disorder — to patients who need it, rather than simply referring them elsewhere.

"An ER doctor would never fail to treat a life-threatening heart attack by treating the patient and activating the cardiology team," Borelli wrote in testimony supporting the bill, "yet I have repeatedly seen colleagues decide not to start buprenorphine for a patient requesting it for opioid use disorder treatment, often due to a misunderstanding of the morbidity and mortality of opioid use disorder."

The proposal arrives as Connecticut grapples with persistent opioid mortality despite national declines in some regions. While the state has made progress expanding access to naloxone and harm reduction services, gaps in medication-assisted treatment continue to drive preventable deaths. Emergency departments, which serve as crisis intervention points for thousands of people experiencing withdrawal or overdose each year, have become flashpoints in debates over whether treating addiction belongs in acute care settings.

Evidence Behind the Mandate

The clinical evidence supporting emergency department-initiated buprenorphine treatment has grown substantially over the past five years. A 2020 study published in JAMA found that patients treated with buprenorphine or methadone experienced a 76% reduction in overdose risk at three months compared to those receiving no medication. The same research documented a 32% reduction in opioid-related emergency department visits among patients maintained on medication-assisted treatment.

More striking is research from Connecticut itself: a Yale University study published in 2023 found that attempting to treat opioid use disorder without medications like buprenorphine or methadone resulted in a 77% higher risk of fatal overdose than providing no treatment at all. The findings suggest that abstinence-only approaches or counseling-focused interventions without pharmacological support not only fail to reduce mortality but may actively increase risk by creating false confidence without addressing the neurobiological drivers of addiction.

Mortality data reinforces the urgency. One study referenced in Borelli's testimony found that patients who received naloxone for overdose reversal face a one-year mortality rate higher than those experiencing life-threatening heart attacks. Yet standard emergency medicine protocols mandate aggressive intervention for cardiac events while treating opioid use disorder as primarily a social problem requiring outpatient management rather than immediate medical response.

The disconnect between evidence and practice persists despite regulatory barriers being largely eliminated. In 2023, federal authorities removed the X-waiver requirement that previously restricted buprenorphine prescribing to specially certified physicians. Today, any DEA-licensed practitioner — including emergency medicine physicians, nurse practitioners, and physician assistants — can legally prescribe buprenorphine. Yet utilization remains low, particularly in emergency settings where institutional culture, lack of training, and concerns about follow-up coordination continue to limit adoption.

Economic Case: Savings, Not Costs

The Connecticut Hospital Association framed SB 365 as an "unfunded mandate" that would increase costs for emergency departments already operating under financial pressure. The organization's concerns center on staff training requirements, follow-up coordination, and potential liability for initiating treatment without guaranteed continuity of care.

Borelli and other addiction medicine advocates argue the opposite: that failing to provide buprenorphine in emergency departments costs Connecticut taxpayers far more than the medication itself. Insurance claims data shows patients prescribed buprenorphine have lower annual healthcare charges across all categories — outpatient visits, inpatient admissions, and emergency department use — with total yearly savings exceeding $20,000 per patient compared to those not receiving medication treatment.

The savings compound when accounting for complications prevented by early treatment initiation. Untreated injection drug use drives heart valve infections requiring open-heart surgery, with average costs approaching $200,000 per case. Spinal infections causing paralysis, kidney failure necessitating dialysis, and anoxic brain injuries requiring lifelong intensive care all appear repeatedly in the medical charts of patients who sought help in emergency departments but were discharged without medication or bridge prescriptions.

"It is devastating to see in a patient's medical chart that they sought treatment in the emergency department, were turned away without starting medication or a bridge prescription, and then went on to have a terrible medical outcome," Borelli noted in her testimony.

The economic argument extends beyond direct medical costs. Patients stabilized on buprenorphine demonstrate higher rates of employment retention, housing stability, and reduced criminal justice system involvement — outcomes that generate savings across multiple public systems while improving individual and family wellbeing. From a Medicaid perspective, preventing even a small fraction of expensive complications could offset the costs of emergency department buprenorphine programs many times over.

What the Bill Requires (and Doesn't)

As currently written, SB 365 would mandate that Connecticut emergency departments offer buprenorphine to patients presenting with opioid use disorder. The legislation does not compel patients to accept treatment — it ensures the option is available for those who want it, rather than leaving the decision to individual emergency physicians' comfort levels or institutional policies.

Advocates have proposed amendments to strengthen implementation. Borelli suggests requiring a minimum seven-day bridge prescription for patients started on buprenorphine in the emergency department, ensuring they have medication to last until they can connect with outpatient follow-up care. Connecticut offers multiple pathways for continuing treatment, including addiction specialists, psychiatrists, primary care providers, and telehealth services, but securing appointments often takes days or weeks. Without bridge prescriptions covering that gap, patients face withdrawal and relapse risk precisely when motivation for treatment is highest.

Another proposed amendment would include methadone as an alternative to buprenorphine for fulfilling the bill's requirement. While methadone typically requires daily supervised dosing at specialized opioid treatment programs rather than emergency department initiation, some advocates argue the legislation should acknowledge it as an evidence-based option for patients who prefer or have succeeded with methadone previously. Emergency departments could facilitate enrollment and provide referrals even if they don't dispense methadone directly.

Additional suggestions include extending the mandate beyond emergency departments to cover patients admitted to medical or psychiatric hospital units. Many people with opioid use disorder encounter the healthcare system through inpatient admissions for infections, injuries, or mental health crises. Requiring those units to offer medication-assisted treatment would expand access to populations who may never visit an emergency department or who need treatment continuation during hospital stays.

The bill does not specify training requirements for emergency department staff, protocols for assessing clinical appropriateness, or metrics for tracking outcomes — implementation details that will likely emerge through regulatory processes if the legislation passes.

Cultural Barriers Beyond Policy

Even if SB 365 becomes law, its effectiveness will depend on changing emergency medicine culture around addiction treatment. Borelli's testimony highlights a paradox: many emergency physicians hold compassionate attitudes toward patients with substance use disorders but still hesitate to prescribe buprenorphine, viewing addiction as requiring specialized expertise beyond their scope of practice.

This perception contrasts sharply with emergency medicine's willingness to manage other complex chronic conditions. Emergency departments routinely treat diabetic ketoacidosis, hypertensive emergencies, and acute psychiatric crises without requiring patients to see specialists before receiving stabilizing treatment. The Clinical Opiate Withdrawal Scale — a simple, validated tool for assessing withdrawal severity — provides objective criteria for buprenorphine initiation comparable to clinical assessments emergency physicians perform dozens of times daily.

Training gaps contribute to hesitation. Medical school and emergency medicine residency curricula often provide minimal addiction medicine education, leaving physicians uncertain about dosing protocols, drug interactions, or how to assess appropriateness for buprenorphine versus other interventions. Unlike managing chest pain or sepsis, where emergency departments have refined protocols and institutional support, addiction treatment often relies on individual physician knowledge and comfort rather than standardized systems.

Institutional factors matter too. Electronic health records may lack templates for addiction assessment or buprenorphine prescribing. Pharmacy contracts might not include buprenorphine on formularies. Discharge planners may be unfamiliar with outpatient addiction treatment resources. Administrative concerns about liability, patient retention, or regulatory scrutiny can create informal barriers even when physicians want to provide treatment.

The cultural challenge extends to how emergency medicine defines its mission. Emergency departments pride themselves on stabilizing life-threatening conditions and facilitating transitions to appropriate care. For conditions like heart attacks or strokes, "stabilization" means aggressive intervention. For opioid use disorder, many emergency physicians have interpreted stabilization as managing acute withdrawal symptoms with supportive care and providing referrals — an approach the evidence increasingly shows is inadequate for reducing mortality.

National Context: Connecticut Joins Growing Movement

Connecticut would not be pioneering emergency department buprenorphine mandates. Several states and large healthcare systems have implemented similar requirements or strong recommendations, generating data on feasibility and outcomes that inform Connecticut's debate.

California's 2021 legislation required emergency departments to offer medications for opioid use disorder and create protocols for initiating treatment. Implementation has been uneven across the state's diverse healthcare landscape, with large urban academic centers adopting comprehensive programs while smaller rural facilities struggle with staffing and training. Early data suggests increased buprenorphine initiations in hospitals that developed robust protocols, though statewide impact on overdose mortality remains difficult to isolate from other interventions.

Rhode Island took a different approach after experiencing a spike in fentanyl deaths, partnering with emergency departments, prisons, and community providers to create coordinated pathways for medication-assisted treatment rather than mandating specific services. The state saw overdose deaths decline 12% in the year following implementation, though multiple concurrent interventions make attributing causation challenging.

Individual healthcare systems have moved faster than state legislatures in some regions. The Denver Health emergency department initiated a program in 2018 offering buprenorphine to patients in withdrawal, with follow-up appointments scheduled before discharge. Two-year data showed 40% of patients engaged in ongoing treatment — a rate addiction medicine specialists consider successful given the population's housing instability, transportation barriers, and previous treatment failures.

The emerging evidence suggests emergency department buprenorphine programs work when designed thoughtfully with adequate resources. Success factors include: dedicated staff champions who provide peer education and consultation; electronic health record integration that makes prescribing as routine as ordering antibiotics; bridge prescriptions lasting long enough to cover follow-up scheduling delays; partnerships with outpatient providers willing to accept rapid referrals; and institutional leadership commitment to treating addiction as medical emergency rather than social problem.

Where programs fail, the pattern is familiar: legislation or mandates without funding for training, technology, or staff time; discharge processes that provide prescriptions but no follow-up coordination; fragmented communication between emergency departments and community treatment providers; and physician resistance based on misconceptions about buprenorphine's safety or effectiveness.

Implementation Questions

If Connecticut legislators pass SB 365, implementation will raise practical questions requiring state guidance, hospital cooperation, and provider buy-in.

Training represents the most immediate need. While emergency physicians possess the clinical skills to assess withdrawal and initiate buprenorphine, many require education on protocols, dosing adjustments, drug interactions with common medications like benzodiazepines, and managing patients who have used fentanyl or other synthetic opioids. The state could develop standardized curricula, fund train-the-trainer programs, or partner with academic medical centers to provide consultation support during early implementation.

Electronic health record modifications would standardize clinical workflows. Templates for addiction screening, Clinical Opiate Withdrawal Scale documentation, buprenorphine prescribing orders, and discharge instructions with follow-up resources could reduce variation and make treatment initiation as routine as prescribing antibiotics for infections. Integrating with the Prescription Drug Monitoring Program would allow emergency physicians to verify patients aren't already receiving buprenorphine from another provider, though this shouldn't be used as a barrier to treatment.

Follow-up coordination presents a more complex challenge. Connecticut has expanded telehealth addiction services, providing rapid access options that didn't exist five years ago. Primary care practices have gradually increased buprenorphine prescribing following X-waiver elimination, creating more community-based treatment slots. Specialized addiction medicine clinics operate in larger cities, though rural areas face significant provider shortages.

Some emergency departments have hired or contracted with addiction navigators — peers in recovery or social workers who help patients schedule follow-up appointments, arrange transportation, and connect with support services. Research from other states shows navigator programs significantly improve treatment engagement rates, but they require funding that SB 365 doesn't explicitly provide.

Insurance coverage shouldn't pose barriers under current regulations. Medicaid and most commercial insurers cover buprenorphine, and federal parity laws require mental health and substance use disorder benefits to match medical/surgical coverage. Prior authorization requirements have been eliminated or streamlined in many plans, though patients may still encounter delays or denials that emergency departments will need protocols for addressing.

Political Outlook

SB 365 faces the typical legislative pathway: review by the Office of Legislative Research and Office of Fiscal Analysis, potential committee amendments, votes in both chambers, and gubernatorial signature. Connecticut's Democratic legislative majority has generally supported harm reduction and addiction treatment expansion, suggesting favorable political conditions.

The Connecticut Hospital Association's opposition could complicate passage. Hospital lobbying organizations wield substantial influence in state capitals, particularly on legislation affecting clinical operations and costs. Their framing of the bill as an unfunded mandate resonates with fiscal conservative concerns about imposing requirements without accompanying appropriations.

Advocates may counter by emphasizing long-term cost savings, leveraging the $20,000 annual per-patient savings data in insurance claims analysis. Framing the bill as protecting Connecticut taxpayers from expensive preventable complications while reducing overdose deaths could broaden political appeal beyond traditional addiction policy coalitions.

Physician advocacy matters significantly. When doctors testify that current practices fail patients and contribute to preventable deaths, legislators pay attention. Borelli's testimony — written as a frontline emergency medicine and addiction medicine physician — carries weight that policy analyst reports cannot match. If emergency physicians beyond addiction medicine specialists endorse the bill, opposition becomes harder to sustain politically.

The legislation's ultimate fate may depend less on partisan divisions than on negotiations over implementation details. Amendments addressing hospital concerns — perhaps phased implementation timelines, state funding for training programs, or liability protections for good-faith treatment efforts — could convert opponents into neutral parties or even supporters.

What Success Would Mean

If Connecticut passes SB 365 and implements it effectively, the state would join jurisdictions demonstrating that emergency departments can serve as critical intervention points in addiction treatment systems rather than missed opportunities.

For patients like those Borelli described — people who arrive in withdrawal, seeking help during moments of crisis when motivation for change peaks — the difference could be life or death. Having a physician offer medication that eliminates withdrawal symptoms, reduces cravings, and blocks the euphoric effects of other opioids provides immediate relief and a pathway toward stability that referral cards cannot match.

For emergency departments, effective implementation would mean treating opioid use disorder like the life-threatening medical condition it is, with protocols and institutional support comparable to other emergencies. Physicians would have the tools, training, and authorization to provide evidence-based care without waiting for specialty consultations or navigating bureaucratic barriers.

For Connecticut's healthcare system, success would mean shifting resources from expensive downstream complications toward preventive interventions. The $200,000 heart surgeries, the dialysis, the ICU admissions for overdose-related brain injuries — many of these tragedies are preventable with early, appropriate addiction treatment. Emergency departments that currently generate costs by sending patients home to deteriorate would become sources of savings by stabilizing them on effective medications.

For families, the impact transcends statistics and cost analyses. When someone they love survives withdrawal and begins recovery because an emergency department offered treatment instead of a referral, when that person remains alive to repair relationships and rebuild their life, the policy stops being abstract and becomes profoundly personal.

Borelli closed her testimony with a comparison that cuts through political and bureaucratic debates: "Not all patients will choose to take medication to treat their opioid use disorder, but not offering it is akin to denying antibiotics for sepsis."

Connecticut legislators will decide in coming months whether that comparison persuades them. For the patients who will arrive at emergency departments this week in withdrawal, hoping someone can help them, the answer will determine whether they encounter barriers or pathways to care.